Abstract
Behçet’s disease (BD) is a systemic vasculitis. Although its clinical characteristics are well defined, the etiology and immune pathogenesis are not clear yet. Neutrophilic vasculitis, which is a consequence of immunological events, is suggested as the underlying pathophysiological mechanism. Adenosine deaminase (ADA) is a non-specific marker of T-lymphocyte activation. A total of 75 patients with BD (45 women and 30 men) and 25 age-matched and gender-matched healthy control volunteers (13 women and 12 men) were included in this study. BD patients were divided into three groups according to their clinical findings: inactive BD patients (group 1, n=25); active BD patients under colchicine treatment (group 2, n=25); and active BD patients without colchicine treatment (group 3, n=25). Plasma ADA (p-ADA) levels of all BD patients and the control group were measured and compared. The relationship between p-ADA levels and disease activity, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels was evaluated and correlated. Patients with BD had significantly higher p-ADA levels (20.6±6.3 U/l) than control subjects (12.8±1.8 U/l; P<0.001). The p-ADA levels of patients with active BD were significantly (for each, P<0.05) higher than those of inactive BD patients or controls. On the other hand, the difference was not significant (P>0.05) between active patients with or without colchicine use. In addition, there were significantly positive correlations between p-ADA, ESR and CRP levels in patients with BD (for each, P<0.05). However, disease duration or haemoglobin levels were not relevant. ADA level may be a valuable and supportive indicator of disease activity and is not affected by colchicine therapy in BD.
Similar content being viewed by others
References
Behçet H (1937) Uber rezidivivierende Aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152–1157
Ghate JV, Jorizzo JL (1999) Behçet’s disease and complex aphthosis. J Am Acad Dermatol 40:1–18
Evereklioglu C (2004) Managing the symptoms of Behçet’s disease. Expert Opin Pharmacother 5:317–328
Evereklioglu C, Yurekli M, Er H, Ozbek E, Hazneci E, Çekmen M (2000) Increased plasma adrenomedullin levels in patients with Behçet’s disease. Dermatology 201:312–315
Evereklioglu C, Inaloz HS, Kirtak N, Doganay S, Bulbul M, Ozerol E, Er H, Ozbek E (2002) Serum leptin concentration is increased in patients with Behçet’s syndrome and is correlated with disease activity. Br J Dermatol 147:331–336
Evereklioglu C, Er H, Turkoz Y, Cekmen M (2002) Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. Mediators Inflamm 11:87–93
Evereklioglu C, Turkoz Y, Er H, Inaloz HS, Ozbek E, Cekmen M (2002) Increased nitric oxide production in patients with Behçet’s disease: is it a new activity marker? J Am Acad Dermatol 46:50–54
Yazici H, Yurdakul S, Hamuryudan V (2001) Behçet’s disease. Curr Opin Rheumatol 13:18–22
Ungerer JPJ, Oosthnizen HM, Bissbort SH, Vermaak WJH (1992) Serum adenosine deaminase: isoenzymes and diagnostic application. Clin Chem 38:1322–1326
Al-Shammary FJ (1997) Adenosine deaminase activity in serum and pleural effusions of tuberculous and non-tuberculous patients. Biochem Mol Biol Int 43:763–769
Sullivan J, Osborne WR, Wedgewood RJ (1977) Adenosine deaminase activity in lymphocytes. Br J Haematol 37:157–158
Kose K, Yazici C, Ascıoglu O (2001) The evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behçet’s disease. Clin Biochem 34:125–129
International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
Giusti G, Galanti B (1984) Colorimetric method. In: Bargmeyer HU (ed) Methods of enzymatic analysis. Verlag Chemie, Weinheim, pp 315–323
Evereklioglu C, Er H (2002) Increased corneal thickness in active Behçet’s disease. Eur J Ophthalmol 12:24–29
Evereklioglu C, Cokkeser Y, Doganay S, Er H, Kizilay A (2001) Audio-vestibular evaluation in patients with Behçet’s syndrome. J Laryngol Otol 115:704–708
Gul A (2001) Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 19:6–12
Kastner DL (1997) Intermittent and periodic arthritic syndromes in arthritis and allied conditions, 13th edn. William J. Kopman Williams and Wilkins, Pennsylvania, USA, pp 1291–1297
Yamashita N, Kaneoka H, Kaneko S, Takeno M, Oneda K, Koizumi H, Kogure M, Inaba G, Sakane T (1997) Role of gamma delta T lymphocytes in the development of Behçet’s disease. Clin Exp Immunol 107:241–247
Baganha MF, Pego A, Maria A, Lima MA, Gaspar EV, Cordeiro AR (1990) Serum and pleural adenosine deaminase: correlation with lymphocytic populations. Chest 97:605–610
Stancikova M, Lukac J, Istok R, Cristalli G, Rovensky J (1998) Serum adenosine deaminase activity and its isoenzyme pattern in patients with systemic lupus erythematosus. Clin Exp Rheumatol 16:583–586
Hitoglou S, Hatzistilianou M, Gougoustamou D, Athanassiadou F, Kotsis A, Catriu D (2001) Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 20:411–416
Meunier P, Filipe P, Emerit I, Freitas J, Guerra Rodrigo F, Adenosine MC (1995) Deaminase in progressive systemic sclerosis. Acta Dermatol Venereol 75:297–299
Gener FA, Turkozkan N, Sever A (1998) The levels of adenosine deaminase activity in knee effusions. Turk J Biochem 13:97–101
Sari RA, Taysi S, Yilmaz O, Bakan N (2003) Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis. Clin Exp Rheumatol 21:87–90
Erkilic K, Evereklioglu C, Cekmen M, Ozkiris A, Duygulu F, Dogan H (2003) Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet’s disease: original contributions/clinical and laboratory investigations. Mediators Inflamm 12:107–116
Fukami R, Ohba S, Ishida K, Nakamura S, Konno M, Ohno S (1994) Serum adenosine deaminase and angiotensin converting enzyme activity in patients with endogenous uveitis. Nippon Ganka Gakkai Zasshi 98:287–292
Mikulikova D, Lukac J, Ondrasik M (1989) The effect of colchicine and its derivatives on the activity of enzyme markers of T-lymphocytes. Cas Lek Cesk 128:1094–1097
Evereklioglu C (2005) Current concepts in the etiology and treatment of Behçet’s disease. Surv Ophthalmol 6 (in press)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Calis, M., Ates, F., Yazici, C. et al. Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet’s disease. Rheumatol Int 25, 452–456 (2005). https://doi.org/10.1007/s00296-005-0612-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-005-0612-z